drugset / Trial / NCT00124124

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

NCT00124124

RandomizedParallel-groupOpen-labelTreatment

Summary

In this study, a melanoma vaccine (5 melanoma peptides) is given with either Montanide or dendritic cells as adjuvants. This randomized trial will establish the safety of both vaccines and compare the 2 vaccine adjuvants in their efficacy to induce immune responses.

Timeline

Start
2005-07
Primary completion
2008-07
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dendritic cells Cell therapy 500000 cells Other
Subject Dendritic cells Cell therapy 3e+06 cells Other
Subject Montanide Other / unclassified Subcutaneous
Background KLH Unknown 100 ug Other

Indications